{"paper_id":"e62cbddc-5252-426d-8b2c-c76a751dfe30","body_text":"Abstract\nFemales of reproductive age can develop endometriosis, an inflammatory gynecological\nillness that is hormone-dependent. The variable lesions that make up the functional endometrium\noutside of the uterus cavity are what set this disorder apart in terms of its clinical and pathological\naspects. Around 10% of women in their reproductive years have endometriosis worldwide,\nwhich significantly lowers their quality of life overall. Infertility and chronic pelvic discomfort are\nthe two main symptoms that significantly affect women's reproductive health and general well-being.\nThe pathophysiological underpinnings of endometriosis remain unclear despite years of intensive\nresearch. Understanding the fundamental mechanisms that produce endometriosis is crucial,\nas demonstrated by the substantial public and private health consequences. This article offers an\noverview of recent advancements in biomarkers regarding endometriosis treatment options, based\non a thorough literature study.\nKeywords: Endometriosis, biomarkers, surgical treatment, cell therapy, diet, interventional therapies, pharmacological treatment.\n[1]\nOrr NL, Sutherland JL, Board EPRA, et al. A patient-oriented workshop on sexual pain and endometriosis: Preliminary evidence for improvements in painful intercourse self-efficacy. J Endometr Pelvic Pain Disord 2023; 2: 100027.\n[2]\nSymons LK, Miller JE, Kay VR, et al. The immunopathophysiology of endometriosis. Trends Mol Med 2018; 24(9): 748-62.\n[http://dx.doi.org/10.1016/j.molmed.2018.07.004] [PMID: 30054239]\n[http://dx.doi.org/10.1016/j.molmed.2018.07.004] [PMID: 30054239]\n[3]\nWang Y, Nicholes K, Shih IM. The origin and pathogenesis of endometriosis. Annu Rev Pathol 2020; 15(1): 71-95.\n[http://dx.doi.org/10.1146/annurev-pathmechdis-012419-032654] [PMID: 31479615]\n[http://dx.doi.org/10.1146/annurev-pathmechdis-012419-032654] [PMID: 31479615]\n[4]\nKeckstein J, Becker CM, Canis M, Feki A. Recommendations for the surgical treatment of endometriosis. Part 2: deep endometriosis. Hum Reprod Open 2020; (1): 002.\n[5]\nAhn SH, Singh V, Tayade C. Biomarkers in endometriosis: Challenges and opportunities. Fertil Steril 2017; 107(3): 523-32.\n[http://dx.doi.org/10.1016/j.fertnstert.2017.01.009] [PMID: 28189296]\n[http://dx.doi.org/10.1016/j.fertnstert.2017.01.009] [PMID: 28189296]\n[6]\nBuppasiri P, Kleebkaow P, Tharanon C, Aue-aungkul A, Kietpeerakool C. Clear cell carcinoma arising in vulvar endometriosis. Case Rep Pathol 2018; 2018: 1-5.\n[http://dx.doi.org/10.1155/2018/4263104] [PMID: 30147978]\n[http://dx.doi.org/10.1155/2018/4263104] [PMID: 30147978]\n[7]\nAllaire C, Bedaiwy MA, Yong PJ. Diagnosis and management of endometriosis. CMAJ 2023; 195(10): E363-71.\n[http://dx.doi.org/10.1503/cmaj.220637] [PMID: 36918177]\n[http://dx.doi.org/10.1503/cmaj.220637] [PMID: 36918177]\n[8]\nAnastasiu CV, Moga MA, Elena Neculau A, et al. Biomarkers for the noninvasive diagnosis of endometriosis: State of the art and future perspectives. Int J Mol Sci 2020; 21(5): 1750.\n[http://dx.doi.org/10.3390/ijms21051750] [PMID: 32143439]\n[http://dx.doi.org/10.3390/ijms21051750] [PMID: 32143439]\n[9]\nFassbender A, Burney R O. Update on biomarkers for the detection of endometriosis. Biomed Res Int 2015.\n[10]\nCho SH, Oh YJ, Nam A, et al. Evaluation of serum and urinary angiogenic factors in patients with endometriosis. Am J Reprod Immunol 2007; 58(6): 497-504.\n[http://dx.doi.org/10.1111/j.1600-0897.2007.00535.x] [PMID: 17997748]\n[http://dx.doi.org/10.1111/j.1600-0897.2007.00535.x] [PMID: 17997748]\n[11]\nGueye NA, Stanhiser J, Valentine L, Kotlyar A, Goodman L, Falcone T. Biomarkers for endometriosis in saliva, urine, and peritoneal fluid. Biomarkers Endometr State Art 2017; pp. 141-63.\n[http://dx.doi.org/10.1007/978-3-319-59856-7_8]\n[http://dx.doi.org/10.1007/978-3-319-59856-7_8]\n[12]\nTokushige N, Markham R, Crossett B, et al. Discovery of a novel biomarker in the urine in women with endometriosis. Fertil Steril 2011; 95(1): 46-9.\n[http://dx.doi.org/10.1016/j.fertnstert.2010.05.016] [PMID: 21168580]\n[http://dx.doi.org/10.1016/j.fertnstert.2010.05.016] [PMID: 21168580]\n[13]\nThambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer’s disease: Challenging but feasible. Biomarkers Med 2010; 4(1): 65-79.\n[http://dx.doi.org/10.2217/bmm.09.84] [PMID: 20387303]\n[http://dx.doi.org/10.2217/bmm.09.84] [PMID: 20387303]\n[14]\nOthman EEDR, Hornung D, Al-Hendy A. Biomarkers of endometriosis. Expert Opin Med Diagn 2008; 2(7): 741-52.\n[http://dx.doi.org/10.1517/17530059.2.7.741] [PMID: 23495814]\n[http://dx.doi.org/10.1517/17530059.2.7.741] [PMID: 23495814]\n[15]\nMartínez S, Garrido N, Coperias JL, et al. Serum interleukin-6 levels are elevated in women with minimal–mild endometriosis. Hum Reprod 2007; 22(3): 836-42.\n[http://dx.doi.org/10.1093/humrep/del419] [PMID: 17062580]\n[http://dx.doi.org/10.1093/humrep/del419] [PMID: 17062580]\n[16]\nPizzo A, Salmeri FM, Ardita FV, Sofo V, Tripepi M, Marsico S. Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosis. Gynecol Obstet Invest 2002; 54(2): 82-7.\n[http://dx.doi.org/10.1159/000067717] [PMID: 12566749]\n[http://dx.doi.org/10.1159/000067717] [PMID: 12566749]\n[17]\nWickiewicz D, Chrobak A, Gmyrek GB, et al. Diagnostic accuracy of interleukin-6 levels in peritoneal fluid for detection of endometriosis. Arch Gynecol Obstet 2013; 288(4): 805-14.\n[http://dx.doi.org/10.1007/s00404-013-2828-6] [PMID: 23553197]\n[http://dx.doi.org/10.1007/s00404-013-2828-6] [PMID: 23553197]\n[18]\nGallinelli A, Chiossi G, Giannella L, Marsella T, Genazzani AD, Volpe A. Different concentrations of interleukins in the peritoneal fluid of women with endometriosis: Relationships with lymphocyte subsets. Gynecol Endocrinol 2004; 18(3): 144-51.\n[http://dx.doi.org/10.1080/09513590310001653044] [PMID: 15255283]\n[http://dx.doi.org/10.1080/09513590310001653044] [PMID: 15255283]\n[19]\nBedaiwy MA, Falcone T. Laboratory testing for endometriosis. Clin Chim Acta 2004; 340(1-2): 41-56.\n[http://dx.doi.org/10.1016/j.cccn.2003.10.021] [PMID: 14734195]\n[http://dx.doi.org/10.1016/j.cccn.2003.10.021] [PMID: 14734195]\n[20]\nWang XQ, Yu J, Luo XZ, et al. The high level of RANTES in the ectopic milieu recruits macrophages and induces their tolerance in progression of endometriosis. J Mol Endocrinol 2010; 45(5): 291-9.\n[http://dx.doi.org/10.1677/JME-09-0177] [PMID: 20732991]\n[http://dx.doi.org/10.1677/JME-09-0177] [PMID: 20732991]\n[21]\nHadisaputra W, Prayudhana S. Serum biomarker profiles of interleukin-6, tumor necrosis factor alpha, matrix-metalloproteinase-2, and vascular endothelial growth factor in endometriosis staging. Med J Indones 2013; 22: 76-82.\n[http://dx.doi.org/10.13181/mji.v22i2.532]\n[http://dx.doi.org/10.13181/mji.v22i2.532]\n[22]\nXavier P, Belo L, Beires J, et al. Serum levels of VEGF and TNF-α and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 2006; 273(4): 227-31.\n[http://dx.doi.org/10.1007/s00404-005-0080-4] [PMID: 16208475]\n[http://dx.doi.org/10.1007/s00404-005-0080-4] [PMID: 16208475]\n[23]\nNirgianakis K, McKinnon B, Ma L, Imboden S, Bersinger N, Mueller MD. Peritoneal fluid biomarkers in patients with endometriosis: A cross-sectional study. Horm Mol Biol Clin Investig 2021; 42(2): 113-22.\n[http://dx.doi.org/10.1515/hmbci-2019-0064] [PMID: 32926606]\n[http://dx.doi.org/10.1515/hmbci-2019-0064] [PMID: 32926606]\n[24]\nLima AP, Moura MD, Rosa e Silva AAM. Prolactin and cortisol levels in women with endometriosis. Braz J Med Biol Res 2006; 39(8): 1121-7.\n[http://dx.doi.org/10.1590/S0100-879X2006000800015] [PMID: 16906287]\n[http://dx.doi.org/10.1590/S0100-879X2006000800015] [PMID: 16906287]\n[25]\nIllera JC, Silván G, Illera MJ, Munro CJ, Lessey BA, Illera M. Measurement of serum and peritoneal fluid LH concentrations as a diagnostic tool for human endometriosis. Reproduction 2001; 121(5): 761-9.\n[http://dx.doi.org/10.1530/rep.0.1210761] [PMID: 11427164]\n[http://dx.doi.org/10.1530/rep.0.1210761] [PMID: 11427164]\n[26]\nShah DK, Correia KF, Harris HR, Missmer SA. Plasma adipokines and endometriosis risk: A prospective nested case-control investigation from the Nurses’ Health Study II. Hum Reprod 2013; 28(2): 315-21.\n[http://dx.doi.org/10.1093/humrep/des411] [PMID: 23188112]\n[http://dx.doi.org/10.1093/humrep/des411] [PMID: 23188112]\n[27]\nGreenbaum H, Galper BEL, Decter DH, Eisenberg VH. Endometriosis and autoimmunity: Can autoantibodies be used as a non-invasive early diagnostic tool? Autoimmun Rev 2021; 20(5): 102795.\n[http://dx.doi.org/10.1016/j.autrev.2021.102795] [PMID: 33722753]\n[http://dx.doi.org/10.1016/j.autrev.2021.102795] [PMID: 33722753]\n[28]\nRandall GW, Gantt PA, Poe-Zeigler RL, et al. Serum antiendometrial antibodies and diagnosis of endometriosis. Am J Reprod Immunol 2007; 58(4): 374-82.\n[http://dx.doi.org/10.1111/j.1600-0897.2007.00523.x] [PMID: 17845208]\n[http://dx.doi.org/10.1111/j.1600-0897.2007.00523.x] [PMID: 17845208]\n[29]\nOzhan E, Kokcu A, Yanik K, Gunaydin M. Investigation of diagnostic potentials of nine different biomarkers in endometriosis. Eur J Obstet Gynecol Reprod Biol 2014; 178: 128-33.\n[http://dx.doi.org/10.1016/j.ejogrb.2014.04.037] [PMID: 24813083]\n[http://dx.doi.org/10.1016/j.ejogrb.2014.04.037] [PMID: 24813083]\n[30]\nYi YC, Wang SC, Chao CC, Su CL, Lee YL, Chen LY. Evaluation of serum autoantibody levels in the diagnosis of ovarian endometrioma. J Clin Lab Anal 2010; 24(5): 357-62.\n[http://dx.doi.org/10.1002/jcla.20415] [PMID: 20872572]\n[http://dx.doi.org/10.1002/jcla.20415] [PMID: 20872572]\n[31]\nNabeta M, Abe Y, Takaoka Y, Kusanagi Y, Ito M. Identification of anti-syntaxin 5 autoantibody as a novel serum marker of endometriosis. J Reprod Immunol 2011; 91(1-2): 48-55.\n[http://dx.doi.org/10.1016/j.jri.2011.04.012] [PMID: 21715015]\n[http://dx.doi.org/10.1016/j.jri.2011.04.012] [PMID: 21715015]\n[32]\nOlkowska-Truchanowicz J, Bocian K, Maksym RB, et al. CD4+ CD25+ FOXP3+ regulatory T cells in peripheral blood and peritoneal fluid of patients with endometriosis. Hum Reprod 2013; 28(1): 119-24.\n[http://dx.doi.org/10.1093/humrep/des346] [PMID: 23019301]\n[http://dx.doi.org/10.1093/humrep/des346] [PMID: 23019301]\n[33]\nCho S, Ahn YS, Choi YS, et al. Endometrial osteopontin mRNA expression and plasma osteopontin levels are increased in patients with endometriosis. Am J Reprod Immunol 2009; 61(4): 286-93.\n[http://dx.doi.org/10.1111/j.1600-0897.2009.00692.x] [PMID: 19260859]\n[http://dx.doi.org/10.1111/j.1600-0897.2009.00692.x] [PMID: 19260859]\n[34]\nScutiero G, Iannone P, Bernardi G, et al. Oxidative stress and endometriosis: A systematic review of the literature. Oxid Med Cell Longev 2017; 2017: 1-7.\n[http://dx.doi.org/10.1155/2017/7265238]\n[http://dx.doi.org/10.1155/2017/7265238]\n[35]\nVerit FF, Erel O, Celik N. Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease. Hum Reprod 2007; 23(1): 100-4.\n[http://dx.doi.org/10.1093/humrep/dem340] [PMID: 18000171]\n[http://dx.doi.org/10.1093/humrep/dem340] [PMID: 18000171]\n[36]\nTian Z, Chang XH, Zhao Y, Zhu HL. Current biomarkers for the detection of endometriosis. Chin Med J 2020; 133(19): 2346-52.\n[http://dx.doi.org/10.1097/CM9.0000000000001063] [PMID: 32858595]\n[http://dx.doi.org/10.1097/CM9.0000000000001063] [PMID: 32858595]\n[37]\nDevi TR, Kadalmani B, Devi CA. Novel methods in diagnosis of endometriosis in future. Int J Reprod Contracept Obstet Gynecol 2022; 11(6): 1824-31.\n[http://dx.doi.org/10.18203/2320-1770.ijrcog20221472]\n[http://dx.doi.org/10.18203/2320-1770.ijrcog20221472]\n[38]\nKocbek V, Vouk K, Mueller MD, Rižner TL, Bersinger NA. Elevated glycodelin-A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecol Endocrinol 2013; 29(5): 455-9.\n[http://dx.doi.org/10.3109/09513590.2013.769516] [PMID: 23461865]\n[http://dx.doi.org/10.3109/09513590.2013.769516] [PMID: 23461865]\n[39]\nDutta M, Joshi M, Srivastava S, Lodh I, Chakravarty B, Chaudhury K. A metabonomics approach as a means for identification of potential biomarkers for early diagnosis of endometriosis. Mol Biosyst 2012; 8(12): 3281-7.\n[http://dx.doi.org/10.1039/c2mb25353d] [PMID: 23079773]\n[http://dx.doi.org/10.1039/c2mb25353d] [PMID: 23079773]\n[40]\nBalan A, Moga MA, Dima L, et al. An overview on the conservative management of endometriosis from a naturopathic perspective: Phytochemicals and medicinal plants. Plants 2021; 10(3): 587.\n[http://dx.doi.org/10.3390/plants10030587] [PMID: 33804660]\n[http://dx.doi.org/10.3390/plants10030587] [PMID: 33804660]\n[41]\nDolmans MM, Donnez J. Emerging drug targets for endometriosis. Biomolecules 2022; 12(11): 1654.\n[http://dx.doi.org/10.3390/biom12111654] [PMID: 36359004]\n[http://dx.doi.org/10.3390/biom12111654] [PMID: 36359004]\n[42]\nLai ZZ, Yang HL, Ha SY, et al. Cyclooxygenase-2 in endometriosis. Int J Biol Sci 2019; 15(13): 2783-97.\n[http://dx.doi.org/10.7150/ijbs.35128] [PMID: 31853218]\n[http://dx.doi.org/10.7150/ijbs.35128] [PMID: 31853218]\n[43]\nWu MH, Wang CA, Lin CC, Chen LC, Chang WC, Tsai SJ. Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab 2005; 90(1): 286-95.\n[http://dx.doi.org/10.1210/jc.2004-1612] [PMID: 15483103]\n[http://dx.doi.org/10.1210/jc.2004-1612] [PMID: 15483103]\n[44]\nVanhie A, Tomassetti C, Peeraer K, Meuleman C, D’Hooghe T. Challenges in the development of novel therapeutic strategies for treatment of endometriosis. Expert Opin Ther Targets 2016; 20(5): 593-600.\n[http://dx.doi.org/10.1517/14728222.2016.1118461] [PMID: 26558646]\n[http://dx.doi.org/10.1517/14728222.2016.1118461] [PMID: 26558646]\n[45]\nCobellis L, Razzi S, De Simone S, et al. The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. Eur J Obstet Gynecol Reprod Biol 2004; 116(1): 100-2.\n[http://dx.doi.org/10.1016/j.ejogrb.2004.02.007] [PMID: 15294376]\n[http://dx.doi.org/10.1016/j.ejogrb.2004.02.007] [PMID: 15294376]\n[46]\nVercellini P, Somigliana E, Viganò P, Abbiati A, Barbara G, Crosignani PG. Endometriosis. Drugs 2009; 69(6): 649-75.\n[http://dx.doi.org/10.2165/00003495-200969060-00002] [PMID: 19405548]\n[http://dx.doi.org/10.2165/00003495-200969060-00002] [PMID: 19405548]\n[47]\nYu T, Lao X, Zheng H. Influencing COX-2 activity by COX related pathways in inflammation and cancer. Mini Rev Med Chem 2016; 16(15): 1230-43.\n[http://dx.doi.org/10.2174/1389557516666160505115743] [PMID: 27145850]\n[http://dx.doi.org/10.2174/1389557516666160505115743] [PMID: 27145850]\n[48]\nIwabe T, Harada T, Tsudo T, et al. Tumor necrosis factor-α promotes proliferation of endometriotic stromal cells by inducing interleukin-8 gene and protein expression. J Clin Endocrinol Metab 2000; 85(2): 824-9.\n[PMID: 10690897]\n[PMID: 10690897]\n[49]\nKoninckx PR, Craessaerts M, Timmerman D, Cornillie F, Kennedy S. Anti-TNF- treatment for deep endometriosis-associated pain: A randomized placebo-controlled trial. Hum Reprod 2008; 23(9): 2017-23.\n[http://dx.doi.org/10.1093/humrep/den177] [PMID: 18556683]\n[http://dx.doi.org/10.1093/humrep/den177] [PMID: 18556683]\n[50]\nD’Hooghe TM, Nugent NP, Cuneo S, et al. Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: A prospective, randomized, placebo- and drug-controlled study. Biol Reprod 2006; 74(1): 131-6.\n[http://dx.doi.org/10.1095/biolreprod.105.043349] [PMID: 16177224]\n[http://dx.doi.org/10.1095/biolreprod.105.043349] [PMID: 16177224]\n[51]\nGuo SW. Epigenetics of endometriosis. Mol Hum Reprod 2009; 15(10): 587-607.\n[http://dx.doi.org/10.1093/molehr/gap064] [PMID: 19651637]\n[http://dx.doi.org/10.1093/molehr/gap064] [PMID: 19651637]\n[52]\nWang L, Tan YJ, Wang M, Chen YF, Li XY. DNA methylation inhibitor 5-Aza-2′-deoxycytidine modulates endometrial receptivity through upregulating HOXA10 expression. Reprod Sci 2019; 26(6): 839-46.\n[http://dx.doi.org/10.1177/1933719118815575] [PMID: 30522400]\n[http://dx.doi.org/10.1177/1933719118815575] [PMID: 30522400]\n[53]\nJeung I, Cheon K, Kim MR. Decreased cytotoxicity of peripheral and peritoneal natural killer cell in endometriosis. BioMed Res Int 2016; 2016: 1-6.\n[http://dx.doi.org/10.1155/2016/2916070] [PMID: 27294113]\n[http://dx.doi.org/10.1155/2016/2916070] [PMID: 27294113]\n[54]\nKapoor R, Stratopoulou CA, Dolmans MM. Pathogenesis of endometriosis: New insights into prospective therapies. Int J Mol Sci 2021; 22(21): 11700.\n[http://dx.doi.org/10.3390/ijms222111700] [PMID: 34769130]\n[http://dx.doi.org/10.3390/ijms222111700] [PMID: 34769130]\n[55]\nLiu Y, Wang J, Zhang X. An update on the multifaceted role of NF-kappaB in endometriosis. Int J Biol Sci 2022; 18(11): 4400-13.\n[http://dx.doi.org/10.7150/ijbs.72707] [PMID: 35864971]\n[http://dx.doi.org/10.7150/ijbs.72707] [PMID: 35864971]\n[56]\nEl-Zayadi AA, Mohamed SA, Arafa M, et al. Anti-IL-6 receptor monoclonal antibody as a new treatment of endometriosis. Immunol Res 2020; 68(6): 389-97.\n[http://dx.doi.org/10.1007/s12026-020-09153-5] [PMID: 32939649]\n[http://dx.doi.org/10.1007/s12026-020-09153-5] [PMID: 32939649]\n[57]\nKolahdouz-Mohammadi R, Shidfar F, Khodaverdi S, et al. Resveratrol treatment reduces expression of MCP-1, IL-6, IL-8 and RANTES in endometriotic stromal cells. J Cell Mol Med 2021; 25(2): 1116-27.\n[http://dx.doi.org/10.1111/jcmm.16178] [PMID: 33325132]\n[http://dx.doi.org/10.1111/jcmm.16178] [PMID: 33325132]\n[58]\nKaramian A, Paktinat S, Esfandyari S, et al. Pyrvinium pamoate induces in-vitro suppression of IL-6 and IL-8 produced by human endometriotic stromal cells. Hum Exp Toxicol 2021; 40(4): 649-60.\n[http://dx.doi.org/10.1177/0960327120964543] [PMID: 33021119]\n[http://dx.doi.org/10.1177/0960327120964543] [PMID: 33021119]\n[59]\nWei X, Shao X. Nobiletin alleviates endometriosis via down-regulating NF-κB activity in endometriosis mouse model. Biosci Rep 2018; 38(3): BSR20180470.\n[http://dx.doi.org/10.1042/BSR20180470]\n[http://dx.doi.org/10.1042/BSR20180470]\n[60]\nMarquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and estrogen signaling in the endometrium: What goes wrong in endometriosis? Int J Mol Sci 2019; 20(15): 3822.\n[http://dx.doi.org/10.3390/ijms20153822] [PMID: 31387263]\n[http://dx.doi.org/10.3390/ijms20153822] [PMID: 31387263]\n[61]\nDonnez J, Dolmans MM. Endometriosis and medical therapy: From progestogens to progesterone resistance to GnRH antagonists: A review. J Clin Med 2021; 10(5): 1085.\n[http://dx.doi.org/10.3390/jcm10051085] [PMID: 33807739]\n[http://dx.doi.org/10.3390/jcm10051085] [PMID: 33807739]\n[62]\nDonnez J, Dolmans MM. GnRH antagonists with or without add-back therapy: A new alternative in the management of endometriosis? Int J Mol Sci 2021; 22(21): 11342.\n[http://dx.doi.org/10.3390/ijms222111342] [PMID: 34768770]\n[http://dx.doi.org/10.3390/ijms222111342] [PMID: 34768770]\n[63]\nTaylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral gnrh antagonist. N Engl J Med 2017; 377(1): 28-40.\n[http://dx.doi.org/10.1056/NEJMoa1700089] [PMID: 28525302]\n[http://dx.doi.org/10.1056/NEJMoa1700089] [PMID: 28525302]\n[64]\nDonnez J, Cacciottola L, Squifflet JL, Dolmans MM. Profile of Linzagolix in the Management of Endometriosis, Including Design, Development and Potential Place in Therapy: A Narrative Review. Drug Des Devel Ther 2023; 17: 369-80.\n[http://dx.doi.org/10.2147/DDDT.S269976] [PMID: 36789095]\n[http://dx.doi.org/10.2147/DDDT.S269976] [PMID: 36789095]\n[65]\nOsuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril 2021; 115(2): 397-405.\n[http://dx.doi.org/10.1016/j.fertnstert.2020.07.055] [PMID: 32912633]\n[http://dx.doi.org/10.1016/j.fertnstert.2020.07.055] [PMID: 32912633]\n[66]\nNgô C, Chéreau C, Nicco C, Weill B, Chapron C, Batteux F. Reactive oxygen species controls endometriosis progression. Am J Pathol 2009; 175(1): 225-34.\n[http://dx.doi.org/10.2353/ajpath.2009.080804] [PMID: 19498006]\n[http://dx.doi.org/10.2353/ajpath.2009.080804] [PMID: 19498006]\n[67]\nCacciottola L, Donnez J, Dolmans MM. Can Endometriosis-Related Oxidative Stress Pave the Way for New Treatment Targets? Int J Mol Sci 2021; 22(13): 7138.\n[http://dx.doi.org/10.3390/ijms22137138] [PMID: 34281188]\n[http://dx.doi.org/10.3390/ijms22137138] [PMID: 34281188]\n[68]\nNgô C, Nicco C, Leconte M, et al. Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo. J Pathol 2010; 222(2): 148-57.\n[http://dx.doi.org/10.1002/path.2756] [PMID: 20821752]\n[http://dx.doi.org/10.1002/path.2756] [PMID: 20821752]\n[69]\nAytan H, Caglar P, Uygur D, Zergeroglu S, Batioglu S. Effect of the immunomodulator leflunomide on the induction of endometriosis in an experimental rat model. Fertil Steril 2007; 87(3): 698-701.\n[http://dx.doi.org/10.1016/j.fertnstert.2006.07.1527] [PMID: 17118364]\n[http://dx.doi.org/10.1016/j.fertnstert.2006.07.1527] [PMID: 17118364]\n[70]\nLeconte M, Santulli P, Chouzenoux S, et al. Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis. Reprod Sci 2015; 22(9): 1171-80.\n[http://dx.doi.org/10.1177/1933719115592708] [PMID: 26169036]\n[http://dx.doi.org/10.1177/1933719115592708] [PMID: 26169036]\n[71]\nOzer H, Boztosun A, Açmaz G, Atılgan R, Akkar OB, Kosar MI. The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model. Reprod Sci 2013; 20(1): 26-32.\n[http://dx.doi.org/10.1177/1933719112452941] [PMID: 22895024]\n[http://dx.doi.org/10.1177/1933719112452941] [PMID: 22895024]\n[72]\nYildiz C, Kacan T, Akkar OB, et al. Effects of pazopanib, sunitinib, and sorafenib, anti-vegf agents, on the growth of experimental endometriosis in rats. Reprod Sci 2015; 22(11): 1445-51.\n[http://dx.doi.org/10.1177/1933719115584448] [PMID: 25963915]\n[http://dx.doi.org/10.1177/1933719115584448] [PMID: 25963915]\n[73]\nLeconte M, Nicco C, Ngô C, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 2011; 179(2): 880-9.\n[http://dx.doi.org/10.1016/j.ajpath.2011.04.020] [PMID: 21718677]\n[http://dx.doi.org/10.1016/j.ajpath.2011.04.020] [PMID: 21718677]\n[74]\nYagyu T, Tsuji Y, Haruta S, et al. Activation of mammalian target of rapamycin in postmenopausal ovarian endometriosis. Int J Gynecol Cancer 2006; 16(4): 1545-51.\n[http://dx.doi.org/10.1136/ijgc-00009577-200607000-00008] [PMID: 16884363]\n[http://dx.doi.org/10.1136/ijgc-00009577-200607000-00008] [PMID: 16884363]\n[75]\nLeconte M, Nicco C, Ngô C, et al. Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis. Am J Pathol 2010; 177(6): 2963-70.\n[http://dx.doi.org/10.2353/ajpath.2010.100375] [PMID: 21057002]\n[http://dx.doi.org/10.2353/ajpath.2010.100375] [PMID: 21057002]\n[76]\nBruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod 2011; 84(1): 106-12.\n[http://dx.doi.org/10.1095/biolreprod.110.086744] [PMID: 20844278]\n[http://dx.doi.org/10.1095/biolreprod.110.086744] [PMID: 20844278]\n[77]\nTaguchi A, Wada-Hiraike O, Kawana K, et al. Resveratrol suppresses inflammatory responses in endometrial stromal cells derived from endometriosis: A possible role of the sirtuin 1 pathway. J Obstet Gynaecol Res 2014; 40(3): 770-8.\n[http://dx.doi.org/10.1111/jog.12252] [PMID: 24320086]\n[http://dx.doi.org/10.1111/jog.12252] [PMID: 24320086]\n[78]\nPark S, Lim W, Bazer FW, Song G. Naringenin induces mitochondria-mediated apoptosis and endoplasmic reticulum stress by regulating MAPK and AKT signal transduction pathways in endometriosis cells. Mol Hum Reprod 2017; 23(12): 842-54.\n[http://dx.doi.org/10.1093/molehr/gax057] [PMID: 29121349]\n[http://dx.doi.org/10.1093/molehr/gax057] [PMID: 29121349]\n[79]\nKapoor R, Sirohi VK, Gupta K, Dwivedi A. Naringenin ameliorates progression of endometriosis by modulating Nrf2/Keap1/HO1 axis and inducing apoptosis in rats. J Nutr Biochem 2019; 70: 215-26.\n[http://dx.doi.org/10.1016/j.jnutbio.2019.05.003] [PMID: 31252288]\n[http://dx.doi.org/10.1016/j.jnutbio.2019.05.003] [PMID: 31252288]\n[80]\nRadomska-Leśniewska DM, Hevelke A, Skopiński P, et al. Reactive oxygen species and synthetic antioxidants as angiogenesis modulators: Clinical implications. Pharmacol Rep 2016; 68(2): 462-71.\n[http://dx.doi.org/10.1016/j.pharep.2015.10.002] [PMID: 26922554]\n[http://dx.doi.org/10.1016/j.pharep.2015.10.002] [PMID: 26922554]\n[81]\nPorpora MG, Brunelli R, Costa G, et al. A promise in the treatment of endometriosis: An observational cohort study on ovarian endometrioma reduction by N-acetylcysteine. Evid Based Complement Alternat Med 2013; 2013: 1-7.\n[http://dx.doi.org/10.1155/2013/240702] [PMID: 23737821]\n[http://dx.doi.org/10.1155/2013/240702] [PMID: 23737821]\n[82]\nAllavena G, Carrarelli P, Del Bello B, Luisi S, Petraglia F, Maellaro E. Autophagy is upregulated in ovarian endometriosis: a possible interplay with p53 and heme oxygenase-1. Fertil Steril 2015; 103(5): 1244-1251.e1.\n[http://dx.doi.org/10.1016/j.fertnstert.2015.02.007] [PMID: 25772769]\n[http://dx.doi.org/10.1016/j.fertnstert.2015.02.007] [PMID: 25772769]\n[83]\nYang H, Hu T, Hu P, Qi C, Qian L. miR‑143‑3p inhibits endometriotic stromal cell proliferation and invasion by inactivating autophagy in endometriosis. Mol Med Rep 2021; 23(5): 356.\n[http://dx.doi.org/10.3892/mmr.2021.11995] [PMID: 33760149]\n[http://dx.doi.org/10.3892/mmr.2021.11995] [PMID: 33760149]\n[84]\nLin YK, Li YY, Li Y, et al. SCM-198 Prevents Endometriosis by Reversing Low Autophagy of Endometrial Stromal Cell via Balancing ERα and PR Signals. Front Endocrinol 2022; 13: 858176.\n[http://dx.doi.org/10.3389/fendo.2022.858176] [PMID: 35784569]\n[http://dx.doi.org/10.3389/fendo.2022.858176] [PMID: 35784569]\n[85]\nFabris L, Brivio S, Cadamuro M, Strazzabosco M. Revisiting epithelial-to-mesenchymal transition in liver fibrosis: clues for a better understanding of the “reactive” biliary epithelial phenotype. Int J Stem Cells 2016.\n[http://dx.doi.org/10.1155/2016/2953727]\n[http://dx.doi.org/10.1155/2016/2953727]\n[86]\nKonrad L, Dietze R, Riaz MA, et al. Epithelial–mesenchymal transition in endometriosis—when does it happen? J Clin Med 2020; 9(6): 1915.\n[http://dx.doi.org/10.3390/jcm9061915] [PMID: 32570986]\n[http://dx.doi.org/10.3390/jcm9061915] [PMID: 32570986]\n[87]\nHsu YW, Chen HY, Chiang YF, Chang LC, Lin PH, Hsia SM. The effects of isoliquiritigenin on endometriosis in vivo and in vitro study. Phytomedicine 2020; 77: 153214.\n[http://dx.doi.org/10.1016/j.phymed.2020.153214] [PMID: 32736296]\n[http://dx.doi.org/10.1016/j.phymed.2020.153214] [PMID: 32736296]\n[88]\nChang LC, Chiang YF, Chen HY, Huang YJ, Liu AC, Hsia SM. The potential effect of fucoidan on inhibiting epithelial-to-mesenchymal transition, proliferation, and increase in apoptosis for endometriosis treatment:In Vivo and In Vitro Study. Biomedicines 2020; 8(11): 528.\n[http://dx.doi.org/10.3390/biomedicines8110528] [PMID: 33266505]\n[http://dx.doi.org/10.3390/biomedicines8110528] [PMID: 33266505]\n[89]\nQi S, Yan L, Liu Z, et al. Melatonin inhibits 17β-estradiol-induced migration, invasion and epithelial-mesenchymal transition in normal and endometriotic endometrial epithelial cells. Reprod Biol Endocrinol 2018; 16(1): 62.\n[http://dx.doi.org/10.1186/s12958-018-0375-5] [PMID: 29935526]\n[http://dx.doi.org/10.1186/s12958-018-0375-5] [PMID: 29935526]\n[90]\nYu MM, Zhou QM. 3,6-dihydroxyflavone suppresses the epithelial-mesenchymal transition, migration and invasion in endometrial stromal cells by inhibiting the Notch signaling pathway. Eur Rev Med Pharmacol Sci 2018; 22(12): 4009-17.\n[PMID: 29949177]\n[PMID: 29949177]\n[91]\nOrellana R, García-Solares J, Donnez J, van Kerk O, Dolmans MM, Donnez O. Important role of collective cell migration and nerve fiber density in the development of deep nodular endometriosis. Fertil Steril 2017; 107(4): 987-995.e5.\n[http://dx.doi.org/10.1016/j.fertnstert.2017.01.005] [PMID: 28238494]\n[http://dx.doi.org/10.1016/j.fertnstert.2017.01.005] [PMID: 28238494]\n[92]\nChung MS, Han SJ. Endometriosis-associated angiogenesis and anti-angiogenic therapy for endometriosis. Front glob women's health 2022; 856316.\n[93]\nMendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9(1): 327-37.\n[PMID: 12538485]\n[PMID: 12538485]\n[94]\nAbbas MA, Disi AM, Taha MO. Sunitinib as an anti-endometriotic agent. Eur J Pharm Sci 2013; 49(4): 732-6.\n[http://dx.doi.org/10.1016/j.ejps.2013.05.021] [PMID: 23747661]\n[http://dx.doi.org/10.1016/j.ejps.2013.05.021] [PMID: 23747661]\n[95]\nGómez R, Abad A, Delgado F, Tamarit S, Simón C, Pellicer A. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertil Steril 2011; 95(3): 882-888.e1.\n[http://dx.doi.org/10.1016/j.fertnstert.2010.10.024] [PMID: 21055747]\n[http://dx.doi.org/10.1016/j.fertnstert.2010.10.024] [PMID: 21055747]\n[96]\nMaharani M, Wahyuni ES, Sutrisno S. Effect of genistein on endometriosis lesion, matrix metalloproteinase-2 and -9 level of endometriosis:In silico and In vivo Study. J Clin Mol Endocrinol 2015; 1(4)\n[97]\nTsuno A, Nasu K, Kawano Y, et al. Fasudil inhibits the proliferation and contractility and induces cell cycle arrest and apoptosis of human endometriotic stromal cells: A promising agent for the treatment of endometriosis. J Clin Endocrinol Metab 2011; 96(12): E1944-52.\n[http://dx.doi.org/10.1210/jc.2011-1503] [PMID: 21917869]\n[http://dx.doi.org/10.1210/jc.2011-1503] [PMID: 21917869]\n[98]\nPellicer N, Galliano D, Herraiz S, Bagger YZ, Arce JC, Pellicer A. Use of dopamine agonists to target angiogenesis in women with endometriosis. Hum Reprod 2021; 36(4): 850-8.\n[http://dx.doi.org/10.1093/humrep/deaa337] [PMID: 33355352]\n[http://dx.doi.org/10.1093/humrep/deaa337] [PMID: 33355352]\n[99]\nTejada MÁ, Santos-Llamas AI, Fernández-Ramírez MJ, Tarín JJ, Cano A, Gómez R. A reassessment of the therapeutic potential of a dopamine receptor 2 agonist (D2-AG) in endometriosis by comparison against a standardized antiangiogenic treatment. Biomedicines 2021; 9(3): 269.\n[http://dx.doi.org/10.3390/biomedicines9030269] [PMID: 33800198]\n[http://dx.doi.org/10.3390/biomedicines9030269] [PMID: 33800198]\n[100]\nDuffy JM, Arambage K, Correa FJ, et al. Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev 2014; (4):\n[101]\nSaunders PTK, Horne AW. Endometriosis: Etiology, pathobiology, and therapeutic prospects. Cell 2021; 184(11): 2807-24.\n[http://dx.doi.org/10.1016/j.cell.2021.04.041] [PMID: 34048704]\n[http://dx.doi.org/10.1016/j.cell.2021.04.041] [PMID: 34048704]\n[102]\nBafort C, Beebeejaun Y, Tomassetti C, Bosteels J, Duffy JM. Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev 2020; (10):\n[103]\nHorne AW, Daniels J, Hummelshoj L, Cox E, Cooper KG. Surgical removal of superficial peritoneal endometriosis for managing women with chronic pelvic pain: Time for a rethink? BJOG 2019; 126(12): 1414-6.\n[http://dx.doi.org/10.1111/1471-0528.15894] [PMID: 31359584]\n[http://dx.doi.org/10.1111/1471-0528.15894] [PMID: 31359584]\n[104]\nSimanski CJP, Althaus A, Hoederath S, et al. Incidence of chronic postsurgical pain (CPSP) after general surgery. Pain Med 2014; 15(7): 1222-9.\n[http://dx.doi.org/10.1111/pme.12434] [PMID: 24716774]\n[http://dx.doi.org/10.1111/pme.12434] [PMID: 24716774]\n[105]\nAlthaus A, Hinrichs-Rocker A, Chapman R, et al. Development of a risk index for the prediction of chronic post-surgical pain. Eur J Pain 2012; 16(6): 901-10.\n[http://dx.doi.org/10.1002/j.1532-2149.2011.00090.x] [PMID: 22337572]\n[http://dx.doi.org/10.1002/j.1532-2149.2011.00090.x] [PMID: 22337572]\n[106]\nKrupa A, Padała O, Putowski M, Konopelko M, Piasek E. Available treatment methods for endometriosis. J Phys Educ Sport 2019; 9(7): 178-84.\n[107]\nStreuli I, de Ziegler D, Santulli P, et al. An update on the pharmacological management of endometriosis. Expert Opin Pharmacother 2013; 14(3): 291-305.\n[http://dx.doi.org/10.1517/14656566.2013.767334] [PMID: 23356536]\n[http://dx.doi.org/10.1517/14656566.2013.767334] [PMID: 23356536]\n[108]\nKim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 2013; 34(1): 130-62.\n[http://dx.doi.org/10.1210/er.2012-1043] [PMID: 23303565]\n[http://dx.doi.org/10.1210/er.2012-1043] [PMID: 23303565]\n[109]\nMcCormack PL. Dienogest. Drugs 2010; 70(16): 2073-88.\n[http://dx.doi.org/10.2165/11206320-000000000-00000] [PMID: 20964453]\n[http://dx.doi.org/10.2165/11206320-000000000-00000] [PMID: 20964453]\n[110]\nBuggio L, Somigliana E, Barbara G, Frattaruolo MP, Vercellini P. Oral and depot progestin therapy for endometriosis: Towards a personalized medicine. Expert Opin Pharmacother 2017; 18(15): 1569-81.\n[http://dx.doi.org/10.1080/14656566.2017.1381086] [PMID: 28914561]\n[http://dx.doi.org/10.1080/14656566.2017.1381086] [PMID: 28914561]\n[111]\nVercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate. Fertil Steril 2005; 84(5): 1375-87.\n[http://dx.doi.org/10.1016/j.fertnstert.2005.03.083] [PMID: 16275232]\n[http://dx.doi.org/10.1016/j.fertnstert.2005.03.083] [PMID: 16275232]\n[112]\nHidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65(2): 129-32.\n[http://dx.doi.org/10.1016/S0010-7824(01)00302-X] [PMID: 11927115]\n[http://dx.doi.org/10.1016/S0010-7824(01)00302-X] [PMID: 11927115]\n[113]\nGodin R, Marcoux V. Vaginally administered danazol: An overlooked option in the treatment of rectovaginal endometriosis? J Obstet Gynaecol Can 2015; 37(12): 1098-103.\n[http://dx.doi.org/10.1016/S1701-2163(16)30075-5] [PMID: 26637082]\n[http://dx.doi.org/10.1016/S1701-2163(16)30075-5] [PMID: 26637082]\n[114]\nSelak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev 2010; 11.\n[115]\nMarjoribanks J, Proctor ML, Farquhar C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. Cochrane Database Syst Rev 2003; (4): CD001751.\n[PMID: 14583938]\n[PMID: 14583938]\n[116]\nKalaitzopoulos DR, Samartzis N, Kolovos GN, et al. Treatment of endometriosis: A review with comparison of 8 guidelines. BMC Womens Health 2021; 21(1): 397.\n[http://dx.doi.org/10.1186/s12905-021-01545-5] [PMID: 34844587]\n[http://dx.doi.org/10.1186/s12905-021-01545-5] [PMID: 34844587]\n[117]\nFerrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother 2018; 19(10): 1109-25.\n[http://dx.doi.org/10.1080/14656566.2018.1494154] [PMID: 29975553]\n[http://dx.doi.org/10.1080/14656566.2018.1494154] [PMID: 29975553]\n[118]\nSoysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: A prospective randomized trial. Hum Reprod 2004; 19(1): 160-7.\n[http://dx.doi.org/10.1093/humrep/deh035] [PMID: 14688176]\n[http://dx.doi.org/10.1093/humrep/deh035] [PMID: 14688176]\n[119]\nPavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil Steril 2012; 98(6): 1370-9.\n[http://dx.doi.org/10.1016/j.fertnstert.2012.08.053] [PMID: 22999792]\n[http://dx.doi.org/10.1016/j.fertnstert.2012.08.053] [PMID: 22999792]\n[120]\nBrown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010; 2010(12): CD008475.\n[PMID: 21154398]\n[PMID: 21154398]\n[121]\nSagsveen M, Farmer JE, Prentice A, et al. Gonadotrophin-releasing hormone analogues for endometriosis: Bone mineral density. Cochrane Database Syst Rev 2003; 2003(4): CD001297.\n[PMID: 14583930]\n[PMID: 14583930]\n[122]\nCarr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: Effects on bone mineral density. Reprod Sci 2014; 21(11): 1341-51.\n[http://dx.doi.org/10.1177/1933719114549848] [PMID: 25249568]\n[http://dx.doi.org/10.1177/1933719114549848] [PMID: 25249568]\n[123]\nStruthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009; 94(2): 545-51.\n[http://dx.doi.org/10.1210/jc.2008-1695] [PMID: 19033369]\n[http://dx.doi.org/10.1210/jc.2008-1695] [PMID: 19033369]\n[124]\nIlhan M, Gürağaç Dereli FT, Akkol EK. Novel drug targets with traditional herbal medicines for overcoming endometriosis. Curr Drug Deliv 2019; 16(5): 386-99.\n[http://dx.doi.org/10.2174/1567201816666181227112421] [PMID: 30588884]\n[http://dx.doi.org/10.2174/1567201816666181227112421] [PMID: 30588884]\n[125]\nShah P, Adlakha A. Laparoscopic management of moderate: Severe endometriosis. J Minim Access Surg 2014; 10(1): 27-33.\n[http://dx.doi.org/10.4103/0972-9941.124463] [PMID: 24501506]\n[http://dx.doi.org/10.4103/0972-9941.124463] [PMID: 24501506]\n[126]\nLee D, Kim SK, Lee JR, Jee BC. Management of endometriosis-related infertility: Considerations and treatment options. Clin Exp Reprod Med 2020; 47(1): 1-11.\n[http://dx.doi.org/10.5653/cerm.2019.02971] [PMID: 32088944]\n[http://dx.doi.org/10.5653/cerm.2019.02971] [PMID: 32088944]\n[127]\nSaltan G, Süntar I, Ozbilgin S, et al. Viburnum opulus L.: A remedy for the treatment of endometriosis demonstrated by rat model of surgically-induced endometriosis. J Ethnopharmacol 2016; 193: 450-5.\n[http://dx.doi.org/10.1016/j.jep.2016.09.029] [PMID: 27647013]\n[http://dx.doi.org/10.1016/j.jep.2016.09.029] [PMID: 27647013]\n[128]\nDemirel MA, Suntar I, Ilhan M, Keles H, Kupeli Akkol E. Experimental endometriosis remission in rats treated with Achillea biebersteinii Afan.: histopathological evaluation and determination of cytokine levels. Eur J Obstet Gynecol Reprod Biol 2014; 175: 172-7.\n[http://dx.doi.org/10.1016/j.ejogrb.2014.01.011] [PMID: 24495394]\n[http://dx.doi.org/10.1016/j.ejogrb.2014.01.011] [PMID: 24495394]\n[129]\nSharma M, Schoop R, Hudson JB. Echinacea as an antiinflammatory agent: the influence of physiologically relevant parameters. Phytother Res 2009; 23(6): 863-7.\n[http://dx.doi.org/10.1002/ptr.2714] [PMID: 19107735]\n[http://dx.doi.org/10.1002/ptr.2714] [PMID: 19107735]\n[130]\nPareek A, Suthar M, Rathore G, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev 2011; 5(9): 103-10.\n[http://dx.doi.org/10.4103/0973-7847.79105] [PMID: 22096324]\n[http://dx.doi.org/10.4103/0973-7847.79105] [PMID: 22096324]\n[131]\nYuan DP, Gu L, Long J, et al. Shikonin reduces endometriosis by inhibiting RANTES secretion and mononuclear macrophage chemotaxis. Exp Ther Med 2014; 7(3): 685-90.\n[http://dx.doi.org/10.3892/etm.2013.1458] [PMID: 24520268]\n[http://dx.doi.org/10.3892/etm.2013.1458] [PMID: 24520268]\n[132]\nAzarnia M, Ejtemaee-Mehr S, Ansari ASA. Effects of Vitex agnus castus on mice fetus development. Acta Med Iran 2007; 45: 263-70.\n[133]\nKüpeli Akkol E, Demirel MA, Bahadır Acıkara O, et al. Phytochemical analyses and effects of Alchemilla mollis (Buser) Rothm. and Alchemilla persica Rothm. in rat endometriosis model. Arch Gynecol Obstet 2015; 292(3): 619-28.\n[http://dx.doi.org/10.1007/s00404-015-3665-6] [PMID: 25700659]\n[http://dx.doi.org/10.1007/s00404-015-3665-6] [PMID: 25700659]\n[134]\nNeto JN, Coelho TM, Aguiar GC, et al. Experimental endometriosis reduction in rats treated with Uncaria tomentosa (cat’s claw) extract. Eur J Obstet Gynecol Reprod Biol 2011; 154(2): 205-8.\n[http://dx.doi.org/10.1016/j.ejogrb.2010.10.002] [PMID: 21030132]\n[http://dx.doi.org/10.1016/j.ejogrb.2010.10.002] [PMID: 21030132]\n[135]\nWichtl M. Herbal drugs and phytopharmaceuticals: A handbook for practice on a scientific basis. (4th ed.), Stuttgart: Medpharm 2004.\n[136]\nXu H, Becker CM, Lui WT, et al. Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. Fertil Steril 2011; 96(4): 1021-1028.e1.\n[http://dx.doi.org/10.1016/j.fertnstert.2011.07.008] [PMID: 21821246]\n[http://dx.doi.org/10.1016/j.fertnstert.2011.07.008] [PMID: 21821246]\n[137]\nWang D, Liu Y, Han J, et al. Puerarin suppresses invasion and vascularization of endometriosis tissue stimulated by 17β-estradiol. PLoS One 2011; 6(9): e25011.\n[http://dx.doi.org/10.1371/journal.pone.0025011] [PMID: 21949833]\n[http://dx.doi.org/10.1371/journal.pone.0025011] [PMID: 21949833]\n[138]\nErgenoÄŸlu AM, Yeniel AÃ, ErbaÅŸ O, et al. Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats. Reprod Sci 2013; 20(10): 1230-6.\n[http://dx.doi.org/10.1177/1933719113483014] [PMID: 23536571]\n[http://dx.doi.org/10.1177/1933719113483014] [PMID: 23536571]\n[139]\nJin Z, Huang J, Zhu Z. Baicalein reduces endometriosis by suppressing the viability of human endometrial stromal cells through the nuclear factor-κB pathway in vitro. Exp Ther Med 2017; 14(4): 2992-8.\n[http://dx.doi.org/10.3892/etm.2017.4860] [PMID: 28912852]\n[http://dx.doi.org/10.3892/etm.2017.4860] [PMID: 28912852]\n[140]\nDi Paola R, Fusco R, Gugliandolo E, et al. Co-micronized palmitoylethanolamide/polydatin treatment causes endometriotic lesion regression in a rodent model of surgically induced endometriosis. Front Pharmacol 2016; 7: 382.\n[http://dx.doi.org/10.3389/fphar.2016.00382] [PMID: 27790149]\n[http://dx.doi.org/10.3389/fphar.2016.00382] [PMID: 27790149]\n[141]\nCosar E, Mamillapalli R, Moridi I, Duleba A, Taylor HS. Serum microRNA biomarkers regulated by simvastatin in a primate model of endometriosis. Reprod Sci 2019; 26(10): 1343-50.\n[http://dx.doi.org/10.1177/1933719118765971] [PMID: 29587611]\n[http://dx.doi.org/10.1177/1933719118765971] [PMID: 29587611]\n[142]\nVivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9(5): 503-10.\n[http://dx.doi.org/10.1038/ni1582] [PMID: 18425107]\n[http://dx.doi.org/10.1038/ni1582] [PMID: 18425107]\n[143]\nThiruchelvam U, Wingfield M, O’Farrelly C. Natural killer cells: Key players in endometriosis. Am J Reprod Immunol 2015; 74(4): 291-301.\n[http://dx.doi.org/10.1111/aji.12408] [PMID: 26104509]\n[http://dx.doi.org/10.1111/aji.12408] [PMID: 26104509]\n[144]\nHoogstad-van Evert J, Paap R, Nap A, van der Molen R. The promises of natural killer cell therapy in endometriosis. Int J Mol Sci 2022; 23(10): 5539.\n[http://dx.doi.org/10.3390/ijms23105539] [PMID: 35628346]\n[http://dx.doi.org/10.3390/ijms23105539] [PMID: 35628346]\n[145]\nMatsuoka S, Maeda N, Izumiya C, Yamashita C, Nishimori Y, Fukaya T. Expression of inhibitory-motif killer immunoglobulin-like receptor, KIR2DL1, is increased in natural killer cells from women with pelvic endometriosis. Am J Reprod Immunol 2005; 53(5): 249-54.\n[http://dx.doi.org/10.1111/j.1600-0897.2005.00271.x] [PMID: 15833103]\n[http://dx.doi.org/10.1111/j.1600-0897.2005.00271.x] [PMID: 15833103]\n[146]\nBinyamin L, Alpaugh RK, Hughes TL, Lutz CT, Campbell KS, Weiner LM. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J Immunol 2008; 180(9): 6392-401.\n[http://dx.doi.org/10.4049/jimmunol.180.9.6392] [PMID: 18424763]\n[http://dx.doi.org/10.4049/jimmunol.180.9.6392] [PMID: 18424763]\n[147]\nBylińska A, Wilczyńska K, Malejczyk J, et al. The impact of HLA-G, LILRB1 and LILRB2 gene polymorphisms on susceptibility to and severity of endometriosis. Mol Genet Genomics 2018; 293(3): 601-13.\n[http://dx.doi.org/10.1007/s00438-017-1404-3] [PMID: 29234882]\n[http://dx.doi.org/10.1007/s00438-017-1404-3] [PMID: 29234882]\n[148]\nCarosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P, LeMaoult J. HLA-G: An immune checkpoint molecule. Adv Immunol 2015; 127: 33-144.\n[http://dx.doi.org/10.1016/bs.ai.2015.04.001] [PMID: 26073983]\n[http://dx.doi.org/10.1016/bs.ai.2015.04.001] [PMID: 26073983]\n[149]\nAmodio G, Sales de Albuquerque R, Gregori S. New insights into HLA -G mediated tolerance. Tissue Antigens 2014; 84(3): 255-63.\n[http://dx.doi.org/10.1111/tan.12427] [PMID: 25132109]\n[http://dx.doi.org/10.1111/tan.12427] [PMID: 25132109]\n[150]\nGalandrini R, Porpora MG, Stoppacciaro A, et al. Increased frequency of human leukocyte antigen–E inhibitory receptor CD94/NKG2A–expressing peritoneal natural killer cells in patients with endometriosis. Fertil Steril 2008; 89(5) (Suppl.): 1490-6.\n[http://dx.doi.org/10.1016/j.fertnstert.2007.05.018] [PMID: 17706207]\n[http://dx.doi.org/10.1016/j.fertnstert.2007.05.018] [PMID: 17706207]\n[151]\nAndré P, Denis C, Soulas C, et al. Anti-NKG2A mAb Is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells. Cell 2018; 175(7): 1731-1743.e13.\n[http://dx.doi.org/10.1016/j.cell.2018.10.014] [PMID: 30503213]\n[http://dx.doi.org/10.1016/j.cell.2018.10.014] [PMID: 30503213]\n[152]\nWu L, Lv C, Su Y, et al. Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol. Gynecol Endocrinol 2019; 35(3): 251-6.\n[http://dx.doi.org/10.1080/09513590.2018.1519787] [PMID: 30325236]\n[http://dx.doi.org/10.1080/09513590.2018.1519787] [PMID: 30325236]\n[153]\nSikora J, Smycz-Kubańska M, Mielczarek-Palacz A, Bednarek I, Kondera-Anasz Z. The involvement of multifunctional TGF-β and related cytokines in pathogenesis of endometriosis. Immunol Lett 2018; 201: 31-7.\n[http://dx.doi.org/10.1016/j.imlet.2018.10.011] [PMID: 30367890]\n[http://dx.doi.org/10.1016/j.imlet.2018.10.011] [PMID: 30367890]\n[154]\nHawinkels LJAC, ten Dijke P. Exploring anti-TGF-β therapies in cancer and fibrosis. Growth Factors 2011; 29(4): 140-52.\n[http://dx.doi.org/10.3109/08977194.2011.595411] [PMID: 21718111]\n[http://dx.doi.org/10.3109/08977194.2011.595411] [PMID: 21718111]\n[155]\nVarga J, Pasche B. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5(4): 200-6.\n[http://dx.doi.org/10.1038/nrrheum.2009.26] [PMID: 19337284]\n[http://dx.doi.org/10.1038/nrrheum.2009.26] [PMID: 19337284]\n[156]\nJiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. OncoImmunology 2016; 5(6): e1163462.\n[http://dx.doi.org/10.1080/2162402X.2016.1163462] [PMID: 27471638]\n[http://dx.doi.org/10.1080/2162402X.2016.1163462] [PMID: 27471638]\n[157]\nOosterlynck DJ, Lacquet FA, Waer M, Koninckx PR. Lymphokine-activated killer activity in women with endometriosis. Gynecol Obstet Invest 1994; 37(3): 185-90.\n[http://dx.doi.org/10.1159/000292556] [PMID: 8005550]\n[http://dx.doi.org/10.1159/000292556] [PMID: 8005550]\n[158]\nVelasco I, Quereda F, Bermejo R, Campos A, Acién P. Intraperitoneal recombinant interleukin-2 activates leukocytes in rat endometriosis. J Reprod Immunol 2007; 74(1-2): 124-32.\n[http://dx.doi.org/10.1016/j.jri.2006.12.001] [PMID: 17210185]\n[http://dx.doi.org/10.1016/j.jri.2006.12.001] [PMID: 17210185]\n[159]\nHalpern G, Schor E, Kopelman A. Nutritional aspects related to endometriosis. Rev Assoc Med Bras 2015; 61(6): 519-23.\n[http://dx.doi.org/10.1590/1806-9282.61.06.519] [PMID: 26841161]\n[http://dx.doi.org/10.1590/1806-9282.61.06.519] [PMID: 26841161]\n[160]\nYouseflu S, Jahanian Sadatmahalleh S, Roshanzadeh G, Mottaghi A, Kazemnejad A, Moini A. Effects of endometriosis on sleep quality of women: does life style factor make a difference? BMC Womens Health 2020; 20(1): 168.\n[http://dx.doi.org/10.1186/s12905-020-01036-z] [PMID: 32778090]\n[http://dx.doi.org/10.1186/s12905-020-01036-z] [PMID: 32778090]\n[161]\nZuraikat FM, St-Onge MP. The influence of diet on sleep. Neurological modulation of sleep. (Watson RR, Preedy VR, Ed.). Academic Press 2020; pp. 205-15.\n[http://dx.doi.org/10.1016/B978-0-12-816658-1.00022-3]\n[http://dx.doi.org/10.1016/B978-0-12-816658-1.00022-3]\n[162]\nCalder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta Mol Cell Biol Lipids 2015; 1851(4): 469-84.\n[http://dx.doi.org/10.1016/j.bbalip.2014.08.010] [PMID: 25149823]\n[http://dx.doi.org/10.1016/j.bbalip.2014.08.010] [PMID: 25149823]\n[163]\nNetsu S, Konno R, Odagiri K, Soma M, Fujiwara H, Suzuki M. Oral eicosapentaenoic acid supplementation as possible therapy for endometriosis. Fertil Steril 2008; 90(4) (Suppl.): 1496-502.\n[http://dx.doi.org/10.1016/j.fertnstert.2007.08.014] [PMID: 18054352]\n[http://dx.doi.org/10.1016/j.fertnstert.2007.08.014] [PMID: 18054352]\n[164]\nVallée A, Lecarpentier Y. Curcumin and endometriosis. Int J Mol Sci 2020; 21(7): 2440.\n[http://dx.doi.org/10.3390/ijms21072440] [PMID: 32244563]\n[http://dx.doi.org/10.3390/ijms21072440] [PMID: 32244563]\n[165]\nArablou T, Pharmacotherapy RK-M-B. Curcumin and endometriosis: Review on potential roles and molecular mechanisms. 2018. Available at: https://www.sciencedirect.com/science/article/pii/S0753332217346838\n[167]\nRicci E, Viganò P, Cipriani S, et al. Physical activity and endometriosis risk in women with infertility or pain. Medicine 2016; 95(40): e4957.\n[http://dx.doi.org/10.1097/MD.0000000000004957] [PMID: 27749551]\n[http://dx.doi.org/10.1097/MD.0000000000004957] [PMID: 27749551]\n[168]\nGonçalves AV, Barros NF, Bahamondes L. The practice of hatha yoga for the treatment of pain associated with endometriosis. J Altern Complement Med 2017; 23(1): 45-52.\n[http://dx.doi.org/10.1089/acm.2015.0343] [PMID: 27869485]\n[http://dx.doi.org/10.1089/acm.2015.0343] [PMID: 27869485]\n[169]\nRakhshaee Z. Effect of three yoga poses (cobra, cat and fish poses) in women with primary dysmenorrhea: A randomized clinical trial. J Pediatr Adolesc Gynecol 2011; 24(4): 192-6.\n[http://dx.doi.org/10.1016/j.jpag.2011.01.059] [PMID: 21514190]\n[http://dx.doi.org/10.1016/j.jpag.2011.01.059] [PMID: 21514190]\n45\n2","source_license":"CC0","license_restricted":false}